ICER Publishes Final Evidence Report on Treatments for Multiple Sclerosis
February 22, 2023
February 22, 2023
BOSTON, Massachusetts, Feb. 22 (TNSrpt) -- The Institute for Clinical and Economic Review issued the following news release on Feb. 20, 2021:
* * *
Independent appraisal committee voted that evidence is not adequate to demonstrate a superior net health benefit for ublituximab when compared to other monoclonal antibodies
Analyses suggest ublituximab and all currently available monoclonal antibodies labeled for MS would achieve common thresholds for cost-eff . . .
* * *
Independent appraisal committee voted that evidence is not adequate to demonstrate a superior net health benefit for ublituximab when compared to other monoclonal antibodies
Analyses suggest ublituximab and all currently available monoclonal antibodies labeled for MS would achieve common thresholds for cost-eff . . .